Search

OBJECTIVE: This study aimed to explore the expression and clinical significance of LINC01197 in serum of patients with pancreatic cancer (PC). PATIENTS AND METHODS: Fifty PC patients (patient group) treated in our hospital from March 2012 to April 2014 were collected, and another 50 normal people (normal group) were collected for physical examination. The LINC01197 expression in serum of the two groups was detected by qRT-PCR method, and the CA 19.9 expression in serum was detected by Roche automatic biochemistry. The expression and diagnostic value of CA 19.9 and LINC01197 in PC were analyzed, and the relationship between LINC01197 and prognosis of PC patients was observed. RESULTS: The CA 19.9 expression in the patient group was significantly higher than that in the normal group (p<0.001). Their area under the curve was 0.791 and 0.944 respectively. The incidence of phases III+IV, lymphatic invasion, and distant metastasis in patients with low expression of LINC01197 is significantly higher than that in those with high expression, and has higher diagnostic value. With the progress of clinical staging, the TNM expression decreased gradually and there were differences between groups (p<0.001). Spearman's test analysis found that the decreased TNM staging of LINC01197 increased gradually (r=-0.816, p<0.001), and the area under the curve of LINC01197 distinguishing phase I and phase II+phase+III+phase IV was 0.930. The 1-year survival rate and 5-year survival rate of patients in low expression group were lower than those in high expression group (p1 year =0.037, p5 year =0.014). Distant metastasis is an independent prognostic factor for PC patients to survive for 1 to 5 years. Differentiation, TNM staging, and LINC01197 are independent prognostic factors for PC patients to survive for 5 years. CONCLUSIONS: The low expression of LINC01197 in PC patients indicates poor prognosis of patients and is expected to be a potential diagnostic and prognostic indicator of PC. [ABSTRACT FROM AUTHOR]

OBJECTIVE: Endometrial cancer (EC) is the most prevalent gynecologic malignancy among women worldwide. Increasing evidence has disclosed the potential role of aryl hydrocarbon receptor (AhR) in the cancer development; however, little is known about its roles in the EC development. In the present study, we evaluated AhR expression in EC tissues as well as cell lines, and investigated the effects of AhR knockdown and exogenous ligand 3-methylchoranthrene (3-MC) on EC cells proliferation and invasion using Ishikawa and ECC-1 cells lines. MATERIALS AND METHODS: In this study, tissue microarray and immunohistochemistry were used to investigate the expression and localization of AhR in EC tissues. RT-PCR and Western blot were performed to detect the AhR expression. AhR specific siRNA was used to knockdown the AhR expression. MTT and transwell assay were carried out to study the EC cells proliferation and invasion, respectively. RESULTS: Our results showed that AhR was highly expressed in the EC tissues and cell lines when compared with its expression in the normal endometrial tissues. AhR siRNA significantly decreased (p < 0.05) AhR protein expression in both Ishikawa and ECC-1 cells. Knockdown of AhR did not alter EC cells proliferation and invasion. However, 3-MC dose-dependently inhibited (p < 0.05) EC cells proliferation via AhR-mediated pathway. CONCLUSIONS: The results from the current application will provide critical information on roles of 3-MC/AhR pathway in mediating EC growth, which could be useful for future therapeutic intervention in this lethal human disease. [ABSTRACT FROM AUTHOR]